Insights On Drug Development
-
Current And New Technologies To Characterize Advanced Therapies: Making The Right Decisions Upstream To Ensure Downstream Success
5/12/2022
Explore the latest strategies and technologies to develop a comprehensive, optimal approach to assay development and product characterization.
-
Artful Taste Masking Improves Patient Compliance
5/12/2022
Taste masking is required for dosage forms that interact with the taste buds. Discover some of the best and most practical taste masking methods to consider for each API.
-
Oral Solutions & Suspensions: The Art Of Pharmacy
5/12/2022
Despite advantages, there are challenges associated with liquid dosage, such as stability and palatability, parameters that need to be considered in the design.
-
Considerations To Get Your CAR T Testing Strategy Right
5/10/2022
Review three considerations to prepare for as part of analytical development prior to finalization of CAR T related FDA guidance.
-
Improving Recovery And Quantitation Of Oligonucleotide Impurities Using MaxPeak HPS Technology
5/5/2022
Evaluate the ACQUITY Premier Solution compared to conventional stainless-steel columns and LC systems having a metal-containing flow path for UV-based analysis of oligonucleotides to address the challenges associated with non-specific adsorption.
-
Automated Data Processing For Mass Confirmation And Impurities Analysis Of Oligonucleotides
5/5/2022
We demonstrate an automated, compliance-ready LC-MS worflow for intact mass confirmation and purity analysis of synthetic oligonucleotides including small interfering RNA (siRNA) and large single guide RNA oligonucleotides and their impurities.
-
Selecting An Appropriate Ion-pairing Agent For Impurity Analysis Of Oligonucleotides
5/4/2022
Learn about method development considerations when selecting an appropriate ion-pairing agent and impurity analysis of dye-conjugated oligonucleotides.
-
Embracing LC-MS Analytical Techniques Into Regulated Laboratories
5/4/2022
We address the additional compliance challenge in biopharma of the requirement of complex analytical instruments that are not traditionally used in highly regulated labs.
-
Process Platforms Vs. Custom Process Development For AAVs And Gene Therapies
5/4/2022
To address cost, time to market, and manufacturing complexity, many developers have turned to turnkey manufacturing platforms. Can these platforms provide the right solution for successful CMC development?
-
Direct LC-MS Characterization Of Glycoform Distribution And Low Molecular Weight Impurities In mAb Process From AmbrĀ® 15 Bioreactors
5/4/2022
We demonstrate a streamlined and robust mAb product monitoring method that is high throughput capable and has the potential to be a fully automated platform for mid-process intraday monitoring of CQAs.